| 2025-11-05 |
详情>>
股本变动：
变动后总股本6016.28万股
变动原因 ▼▲
- 原因：
- From June 30, 2025 to September 30, 2025
Issuance of common stock, exercise of stock options
Issuance of common stock, vested restricted stock units
|
| 2025-11-05 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.46美元,归母净利润-2738.52万美元,同比去年增长31.61%
|
| 2025-08-13 |
详情>>
内部人交易：
Alfieri Michael股份增加2500.00股
|
| 2025-08-07 |
详情>>
业绩披露：
2025年中报每股收益-0.33美元,归母净利润-1969.68万美元,同比去年增长20.99%
|
| 2025-05-14 |
详情>>
业绩披露：
2025年一季报每股收益-0.17美元,归母净利润-992.95万美元,同比去年增长-22.86%
|
| 2025-04-25 |
股东大会：
将于2025-06-10召开股东大会
会议内容 ▼▲
- 1.To elect the three directors named in the proxy statement accompanying this notice to serve as Class II directors until the annual meeting held in 2028, or until their successors are duly elected and qualified.
2.To ratify the appointment of BDO USA, P.C. as Aldeyra Therapeutics, Inc.’s independent registered public accounting firm for the year ending December 31, 2025.
3.To approve, on a non-binding, advisory basis, the compensation of our named executive officers as described in this proxy statement.
4.To transact such other business as may properly come before the annual meeting or any adjournment thereof.
|
| 2025-04-03 |
复牌提示：
2025-04-03 07:55:00 停牌，复牌日期 2025-04-03 08:30:00
|
| 2025-02-28 |
详情>>
业绩披露：
2024年年报每股收益-0.94美元,归母净利润-5585.14万美元,同比去年增长-48.77%
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.67美元,归母净利润-4004.27万美元,同比去年增长-22.12%
|
| 2024-08-01 |
详情>>
业绩披露：
2024年中报每股收益-0.42美元,归母净利润-2492.97万美元,同比去年增长-1.33%
|
| 2024-05-02 |
详情>>
业绩披露：
2024年一季报每股收益-0.14美元,归母净利润-808.21万美元,同比去年增长48.24%
|
| 2024-04-22 |
股东大会：
将于2024-06-04召开股东大会
会议内容 ▼▲
- 1.To elect the two directors named in the proxy statement accompanying this notice to serve as Class I directors until the annual meeting held in 2027, or until their successors are duly elected and qualified.
2.To ratify the appointment of BDO USA, P.C. as Aldeyra Therapeutics, Inc.’s independent registered public accounting firm for the year ending December 31, 2024.
3.To approve, on a non-binding, advisory basis, the compensation of our named executive officers as described in this proxy statement.
|
| 2024-03-07 |
详情>>
业绩披露：
2023年年报每股收益-0.64美元,归母净利润-3754.25万美元,同比去年增长39.47%
|
| 2023-11-03 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.56美元,归母净利润-3278.95万美元,同比去年增长33.25%
|
| 2023-08-03 |
详情>>
业绩披露：
2023年中报每股收益-0.42美元,归母净利润-2460.27万美元,同比去年增长28.83%
|
| 2023-05-23 |
股东大会：
将于2023-06-30召开股东大会
会议内容 ▼▲
- 1.To elect the two directors named in the proxy statement accompanying this notice to serve as Class III directors until the annual meeting held in 2026, or until their successors are duly elected and qualified.
2.To ratify the appointment of BDO USA, LLP as Aldeyra Therapeutics, Inc.’s independent registered public accounting firm for the year ending December 31, 2023.
3.To approve, on a non-binding, advisory basis, the compensation of our named executive officers as described in this proxy statement.
4.To approve the adoption of the Aldeyra Therapeutics, Inc. 2023 Equity Incentive Plan (the “2023 Equity Incentive Plan”) as described in this proxy statement.
5.To transact such other business as may properly come before the annual meeting or any adjournment thereof.
|
| 2023-03-09 |
财报披露：
美东时间 2023-03-09 盘前发布财报
|
| 2022-04-25 |
股东大会：
将于2022-06-07召开股东大会
会议内容 ▼▲
- 1.To elect the three directors named in the proxy statement accompanying this notice to serve as Class II directors until the annual meeting held in 2025 and until their successors are duly elected and qualified.
2.To ratify the appointment of BDO USA, LLP as Aldeyra Therapeutics, Inc.’s independent registered public accounting firm for the year ending December 31, 2022.
3.To approve, on a non-binding, advisory basis, the compensation of our named executive officers as described in this proxy statement.
4.To transact such other business as may properly come before the annual meeting or any adjournment thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-14 |
股东大会：
将于2021-06-08召开股东大会
会议内容 ▼▲
- 1.To elect the two directors named in the proxy statement accompanying this notice to serve as Class I directors until the annual meeting held in 2024 and until their successors are duly elected and qualified.
2.To ratify the appointment of BDO USA, LLP as Aldeyra Therapeutics, Inc.’s independent registered public accounting firm for the year ending December 31, 2021
3.To approve, on a non-binding, advisory basis, the compensation of our named executive officers as described in this proxy statement.
|
| 2020-04-27 |
股东大会：
将于2020-06-09召开股东大会
会议内容 ▼▲
- 1.To elect the two directors named in the proxy statement accompanying this notice to serve as Class III directors until the annual meeting held in 2023 and until their successors are duly elected and qualified.
2.To ratify the appointment of BDO USA, LLP as Aldeyra Therapeutics, Inc.’s independent registered public accounting firm for the year ending December 31, 2020.
3.To approve, on a non-binding, advisory basis, the compensation of our named executive officers as described in this proxy statement.
4.To approve, on a non-binding, advisory basis, the frequency with which future stockholder advisory votes on the compensation of our named executive officers will be conducted.
5.To transact such other business as may properly come before the annual meeting or any adjournment thereof.
|
| 2019-04-22 |
股东大会：
将于2019-06-04召开股东大会
会议内容 ▼▲
- 1.To elect the three directors named in the proxy statement accompanying this notice to serve as Class II directors until the annual meeting held in 2022 and until their successors are duly elected and qualified.
2.To ratify the appointment of BDO USA, LLP as Aldeyra Therapeutics, Inc.’s independent registered public accounting firm for the year ending December 31, 2019.
3.To approve an amendment to Aldeyra Therapeutics, Inc.’s 2013 Equity Incentive Plan (2013 Plan) to remove the annual limitations on the number of shares subject to awards that may be issued to eligible service providers under the 2013 Plan.
|
| 2018-04-25 |
股东大会：
将于2018-06-07召开股东大会
会议内容 ▼▲
- 1.To elect the two directors named in the proxy statement accompanying this notice to serve as Class I directors until the annual meeting held in 2021 and until their successors are duly elected and qualified.
2.To ratify the appointment of BDO USA, LLP as Aldeyra Therapeutics, Inc.’s independent registered public accounting firm for the year ending December 31, 2018.
3.To approve an amendment to Aldeyra Therapeutics’ 2013 Equity Incentive Plan (2013 Plan) to modify the automatic “evergreen” provisions regarding the number of shares to be annually added to the 2013 Plan and implement limitations on the value of equity that may be granted under the 2013 Plan to a non-employee director during a calendar year.
4.To transact such other business as may properly come before the annual meeting or any adjournment thereof.
|
| 2017-04-24 |
股东大会：
将于2017-06-08召开股东大会
会议内容 ▼▲
- 1.To elect the two directors named in the proxy statement accompanying this notice to serve as Class III directors until the annual meeting held in 2020 and until their successors are duly elected and qualified.
2.To ratify the appointment of BDO USA, LLP as Aldeyra Therapeutics, Inc.’s independent registered public accounting firm for the year ending December 31, 2017.
3.To transact such other business as may properly come before the annual meeting or any adjournment thereof.
|
| 2016-04-25 |
股东大会：
将于2016-06-09召开股东大会
会议内容 ▼▲
- 1.To elect the two directors named in the proxy statement accompanying this notice to serve as Class II directors until the annual meeting held in 2019 and until their successors are duly elected and qualified.
2.To ratify the appointment of BDO USA, LLP as Aldeyra Therapeutics, Inc.’s independent registered public accounting firm for the year ending December 31, 2016.
3.To approve an amendment to our 2013 Equity Incentive Plan (2013 Plan) to increase the aggregate number of shares authorized for issuance under the plan.
4.To approve our 2016 Employee Stock Purchase Plan.
|